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Abstract
Background
Older adults are often excluded from clinical trials. Decision making for administration of
statins to older patients with diabetes mellitus (DM) is under debate, particularly in frail older
patients with comorbidity and high mortality risk. We tested the hypothesis that statin treat-
ment in older patients with DM was differentially effective across strata of mortality risk
assessed by the Multidimensional Prognostic Index (MPI), based on information collected
with the Standardized Multidimensional Assessment Schedule for Adults and Aged Per-
sons (SVaMA).
Methods
In this retrospective observational study, we estimated the mortality risk in 1712 community-
dwelling subjects with DM 65 years who underwent a SVaMA evaluation to establish
accessibility to homecare services/nursing home admission from 2005 to 2013 in the
Padova Health District, Italy. Mild (MPI-SVaMA-1), moderate (MPI-SVaMA-2), and high
(MPI-SVaMA-3) risk of mortality at baseline and propensity score-adjusted hazard ratios
(HR) of three-year mortality were calculated according to statin treatment.
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Results
Higher MPI-SVaMA scores were associated with lower rates of statin treatment (MPI-
SVaMA-1 = 39% vs MPI-SVaMA-2 = 36% vs MPI-SVaMA-3 = 24.9%. p<0.001) and higher
three-year mortality (MPI-SVaMA-1 = 12.9% vs MPI-SVaMA-2 = 24% vs MPI-SVaMA-3 =
34.4%, p<0.001). After adjustment for propensity score quintiles, statin treatment was signif-
icantly associated with lower three-year mortality irrespective of MPI-SVaMA group (interac-
tion test p = 0.303). HRs [95% confidence interval (CI)] were 0.19 (0.14–0.27), 0.28 (0.21–
0.36), and 0.26 (0.20–0.34) in the MPI-SVaMA-1, MPI-SVaMA-2, and MPI-SVaMA-3
groups, respectively. Subgroup analyses showed that statin treatment was also beneficial
irrespective of age. HRs (95% CI) were 0.21 (0.15–0.31), 0.26 (0.20–0.33), and 0.26 (0.20–
0.35) among patients aged 65–74, 75–84, and 85 years, respectively (interaction test
p=0.812).
Conclusions
Statin treatment was significantly associated with reduced three-year mortality indepen-
dently of age and multidimensional impairment in community-dwelling frail older patients
with DM.
Introduction
Clinical trial data of treatment with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors
(statins) in persons over 75–80 years are scarce [1, 2], and the benefits and potential harms of
statin treatment are frequently disputed. This especially applies to persons without cardiovas-
cular disease [3] and to persons who are frail and multimorbid and therefore assessed to be at
heightened risk of statin adverse effects [4].
The recently discovered increased risk of diabetes mellitus (DM) during statin treatment,
suggested by observational studies [5], randomized clinical trials (RCTs) [6], and large meta-
analyses [7], may have further fuelled these concerns. In particular, in a large meta-analysis on
13 statin trials with 91140 participants, meta-regression showed that risk of development of
DM with statins was highest in trials with older participants [7], a group for which the absolute
benefit of statin treatment would also be greater. Actually, there are very limited data assessing
the impact of statins on older patients with DM [8] and the available evidence on other out-
comes such as frailty, physical and cognitive function, and institutionalization is mixed [9–12].
On the other hand, there is also a danger that older patients with DM are unnecessarily
deprived of potentially useful therapy [13, 14]. Recent studies have shown that clinical decision
making on statin prescription in older patients only seldom considers risk stratification [15,
16], resulting in many hospitalized or community-dwelling older patients with DM not receiv-
ing statin therapy. Certainly, the clinical decision about statin therapy in older patients with
DM is very challenging and should take into account both the risk of complications and the
expected future survival time [1].
Many lines of research demonstrated that mortality risk stratification in older patients
should be based on information on comorbidity and functional status [17], and it is best per-
formed using a multidimensional Comprehensive Geriatric Assessment (CGA) that integrate
information of several domains of health and function [18]. Recently, a Multidimensional
Prognostic Index (MPI) derived from a standardized CGA has been developed and validated
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for mortality risk assessment in several independent cohorts of hospitalized [19] and commu-
nity-dwelling older subjects [20] with acute or chronic diseases. The aim of the present study
was to test the hypothesis that statin treatment in community-dwelling frail older patients with
DM is differentially effective across strata of mortality risk.
Methods
Study Population
This was a retrospective observational study conducted according to the World Medical Asso-
ciation's 2008 Declaration of Helsinki, the guidelines for Good Clinical Practice, and the
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines
[21]. All consecutive community-dwelling older subjects aged 65 years and older who un-
derwent a CGA-based multidimensional assessment according to the Standardized Multidi-
mensional Assessment Schedule for Adults and Aged Persons (Scheda per la Valutazione
Multidimensionale delle persone adulte e Anziane) (SVaMA) [20] from January 1st 2005 to
December 31st 2013 were screened for inclusion in the study. Inclusion criteria were: [1] diag-
nosis of DM according to the ICD9 250 and subgroups or according to the main diagnosis
record T90 (“diabetes mellitus”) of the SVAMA; [2] a SVaMA evaluation within 2 months
from the date of the first registration of the DM diagnosis in the database. The Institutional
Review Board of the Social and Health-Care Local Unit (Unità Locale Socio Sanitaria, ULSS)
16, Padova, Italy approved this retrospective observational study. Informed consent was given
by participants who underwent SVaMA evaluation and/or their proxies for their clinical rec-
ords to be used in clinical studies. All patient records and information were anonymized and
de-identified prior to the analysis. For statin users, the “enrollment” was defined as the first
statin prescription which succeed the date of the registration of the DM diagnosis. For statin
non-users, the “enrollment” was defined as the date of the SVaMA completion which succeed
the date of the first registered DM diagnosis in the database. If the date of SVaMA completion
preceded the date of the DM diagnosis registration, the time interval between these dates was
lower than 2 months. Subjects were followed for a mean follow-up of 3.20±2.76 years. Vital sta-
tus was assessed by consulting the Registry Offices of the cities in which the patients were resi-
dents at the time of the evaluation. Dates of death were identified from death certificates. All
the data regarding the evaluations were extracted from the Administrative Repository Database
of the ULSS 16, Padova, Italy.
The Multidimensional Prognostic Index (MPI) Based on the SVaMA
The SVaMA is the officially recommended multidimensional assessment schedule used
since 2000 by the health personnel of the National Health Care System (NHS) to perform a
multidimensional assessment in community-dwelling older persons introduced by the Veneto
Regional Health System since 2000 to establish accessibility to some health care resources
(homecare services or nursing home admission) [20]. In order to calculate the MPI, the follow-
ing domains of the SVaMA were considered: 1) age, 2) sex, 3) main diagnosis, 4) Nursing Care
Needs (VIP) evaluated according to a validated numeric scale including 11 items that estimated
the nursing care needs of the older subject; 5) Cognitive status (VCOG), evaluated by the Short
Portable Mental Status Questionnaire (SPMSQ); 6) the pressure sores risk (VPIA), evaluated
by the Exton-Smith Scale; 7) the activities of daily living (VADL) and 8) mobility (VMOB)
evaluated by the Barthel Index; 9) social support (VSOC), evaluated by a numeric scale of 16
items that explores the presence of a support network during the day and the night. The
SVaMA instrument (Italian version) is available on-line at the following address: http://www.
uneba.org/regione-veneto-nuova-svama-e-nuova-svamdi/.
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To calculate the MPI from the SVaMA, a weighted sum of each individual domain (Di) was
computed (raw formula). Weights (Si) were estimated from a multivariate Cox proportional
hazard model for 1-year mortality prediction. Each weighted sum (R = ∑(Si
. Di)) was then nor-
malized into a range that varies from 0 (lowest risk) to 1 (highest risk), subtracting the observed
raw minimum value and then dividing such difference by the observed range (minimum to
maximum span). The MPI-SVaMA was expressed as a continuous value from 0 (lower risk) to
1.0 (higher risk of mortality). The RECursive Partition and AMalgamation (RECPAM) algo-
rithm [22] was used to identify subgroups of patients at different risks for mortality [20]. The
following cut offs were estimated for the normalized MPI-SVaMA one-year mortality predic-
tion: 0–0.33 (MPI-SVaMA-1 mild risk), 0.34–0.47 (MPI-SVaMA-2 moderate risk), 0.48–1.0
(MPI-SVaMA-3 severe risk). To calculate the MPI-SVaMA at 1 month and at 1 year, software
for Windows may be downloaded (available for free) at the following address: http://www.
mpiage.eu/home/about-mpi-svama (English version). Further information on reliability, accu-
racy, calibration and validation of the MPI based on the SVaMA can be found elsewhere [20].
Drug Treatment Assessment
Our cohort was linked to the Pharmaceutical Prescription database of the Azienda ULSS 16
Padova to extract the individual medication use. Statin and other drug prescriptions were
determined according to the Anatomical Therapeutic Chemical (ATC) codes. Statin prescrip-
tion was determined by C10 ATC code. Individuals were considered statin-users if they
received statin prescriptions after the first registered evidence of the DM diagnosis. In the pres-
ent study, we included all statin-users who achieved a treatment adherence coverage, i.e., the
ratio between treatment duration (in days) and individual follow-up duration (in days) of at
least 100% for the first year, 90% and 80% when considering the outcome at two and three
years of follow-up, respectively. We defined statin non-users, the older individuals who never
received statin prescriptions. As a proxy of patients’ polypharmacy, we used the mean monthly
past treatment rate defined as the total number of drug boxes taken before the enrollment
divided by the total number of months between the first prescription and the enrollment.
Statistical Analysis
Baseline characteristics were reported as frequencies (percentages) and mean±standard devia-
tion (SD), for categorical and continuous variables, respectively. Comparisons between men
and women were performed using Pearson chi-square test and Mann-Whitney U test, whereas
tests for linear trend across MPI grades were performed using ANOVA models or Mantel-
Haenszel chi-square tests for continuous and categorical variables, respectively. Mortality inci-
dence rates were computed as the number of new events per 100 person-years and compared
using a Poisson regression models. To control possible confounding effects on the association
between statin treatment and mortality risk, the propensity score (PS) methodology was
applied [23]. PS logistic regression models were built to predict the probability to receive statin
according to all variables used for the calculation of MPI-SVaMA at treatment assignment: age,
sex, VIP, VCOG, VPIA, VADL, VMOB, VSOC, the main diagnoses of fractures, cancer,
dementia, stroke, hypokinetic syndrome and cardiovascular, respiratory neurological or other
diseases and the past treatment rate (in tertiles). PS logistic models were selected in a step-wise
fashion, and model-building stopped when adequate balance of covariates was achieved [23].
Residual imbalances of covariates in PS quintiles were assessed at each step with a two-way
analysis of variance (ANOVA) where each confounder was considered as an outcome and PS
quintiles and treatment as factors. Overlapping of PS between treatment and control groups
was also checked, and non-overlapping subjects were excluded from the analyses. Separate PS
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logistic models were run for the overall sample and MPI grade subgroups. Multivariable and
PS-quintiles adjusted Cox regression models were used to assess the effect of statin use on
three-years mortality, and results were reported as hazard ratios (HRs) along with their 95%
confidence intervals (95% CIs). In addition, to check the robustness of our findings, a 5 to 1
greedy 1:1 PS matching algorithm was performed. PS 1:1 matching identified a unique matched
control for each treated patient according to their PS. Adequacy of covariate balance in the
matched sample was eventually assessed with McNemar or Wilcoxon’s signed rank test. For
the overall sample and for specific MPI-SVaMA grade subgroups, adjusted HRs of statin use
for three-year mortality were reported along with total number of events, total subjects per
group and mortality rates. Multivariable models included: statin treatment, age, sex, the main
diagnoses, all domains of MPI-SVaMA and the past treatment rate as covariates. As the PS
matched sample did not consist of independent observations, a marginal survival model with
robust standard errors was used. P-values assessing the presence of a heterogeneous effect of
statin treatment between MPI-SVaMA risk subgroups were also calculated and reported. Two-
sided P-values<0.05 were considered statistically significant. All the analyses were performed
using SAS Release 9.1.3 (SAS Institute, Cary, NC).
Results
Characteristics of the Study Population
Initially, 1899 subjects aged 65 years and older with a diagnosis of DM were screened. Of these,
187 subjects (9.8%) were excluded because their SVaMA evaluation was not performed within
2 months from the date of the first registration of the DM diagnosis (86 subjects) or due to a
statin low treatment adherence coverage during follow-up as defined above (101 subjects).
Therefore, the study population included 1712 patients, 740 men (43.2%) and 972 women
(56.8%) with a mean age of 81.1±7.33 years. Men were younger (79.01±7.1 vs 82.71±7.3 years,
p<0.001), had higher MPI mean values (0.46±0.2 vs 0.35±0.16, p<0.001), higher VIP (10.32
±9.3 vs 8.31±8.5, p<0.001), higher prevalence of cancer (27.98% vs 11.32%, p<0.001), and
showed significantly higher mortality incidence rates at three years of follow-up (25.8% vs
18.8%, p<0.001) than women. Women were significantly more cognitively impaired as mea-
sured by VCOG (men = 4.39±3.6 vs women = 5.16±3.5, p<0.001) and had higher prevalence
of dementia (men = 16.08% vs women = 23.77%, p<0.001). No significant differences between
sexes were observed in the overall past treatment rates. The proportion of patients starting
statin treatment was higher in men than in women (65.94% vs 59.2%, p<0.001).
Table 1 shows the characteristics of patients divided according to their MPI-SVaMA grade:
603 patients (35.2%) were in MPI-SVaMA-1 mild-risk, 662 patients (38.7%) in MPI-SVaMA-2
moderate-risk and 447 patients (26.1%) in MPI-SVaMA-3 severe-risk of mortality. Patients
with higher MPI-SVaMA values were more likely to be males (p for trend<0.001) and older (p
for trend<0.001) and had significantly higher VADL, VCOG, VIP, VMOB, VPIA, and VSOC
scores (all domains p for trend<0.001). Three-year mortality incidence rates were MPI-S-
VaMA-1: 12.9%, MPI-SVaMA-2: 24.0%, and MPI-SVaMA-3: 34.4% (p for trend<0.001).
Overall, 1064 patients with DM (62.15% of the total study population with DM) were
treated with statins. The treated patients (Table 2) were younger (p = 0.001), had lower
impairment in VCOG (p = 0.002), VPIA (p = 0.02), VADL (p = 0.001), VMOB (p<0.001)
scores and lower MPI-SVaMA values (p<0.001) than untreated patients. Moreover, patients
treated with statins were more frequently in the MPI-SVaMA-1 group (39% vs 29%, p<0.001)
and in the highest tertile of medication number (3-tertile, 40.23% vs. 22.53%, p<0.001) than
patients untreated with statins.
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Association of Statin Treatment with Mortality
In the whole study population, multivariable analysis (adjusted for age, sex, main diagnoses, all
MPI-SVaMA domains, and past treatment) showed that, during the three years of follow-up,
statin treatment was associated with lower mortality risk (Table 3). Statin treatment was signifi-
cantly associated with lower three-year mortality risk, irrespective of the MPI-SVaMA grade
(Table 3). In the whole population, the significant association between statin treatment and
lower three-year mortality was confirmed even after the adjustment for PS quintiles. Similarly,
statin treatment was significantly associated with lower mortality risk within each class of
MPI-SVaMA. The HRs (95%CI) were: 0.19 (0.14–0.27), 0.28 (0.21–0.36), and 0.26 (0.20–0.34)
in patients in MPI-SVaMA-1, MPI-SVaMA-2, and MPI-SVaMA-3 respectively, although no
differential effectiveness on mortality risk was found across MPI-SVaMA groups (interaction
test p = 0.303). Finally, the association between statin treatment and reduction of mortality was
Table 1. Baseline characteristics of community-dwelling older patients with diabetes mellitus divided according to their Multidimensional Prog-
nostic Index (MPI) grade based on the Standardized Multidimensional Assessment Schedule for Adults and Aged Persons (SVaMA).
All (n = 1712) MPI-SVaMA-1 Mild risk
(n = 603)
MPI-SVaMA-2 Moderate
risk (n = 662)
MPI-SVaMA-3 Severe risk
(n = 447)
p-value (test for
trend)
Patients (%) 100% 35.2% 38.7% 26.1% ——
Age at SVaMA evalutation
(years)
81.11±7.33 79.13±6.84 81.99±7.40 82.47±7.30 <0.001
Sex (n males, %) 740 (43.22) 188 (31.18) 275 (41.54) 277 (61.97) <0.001
VADL 40.23±19.12 21.25±15.09 46.77±12.82 56.15±6.82 <0.001
VCOG 4.83±3.56 3.28±3.12 4.97±3.43 6.71±3.36 <0.001
VIP 9.18±8.91 4.04±4.95 7.64±6.74 18.40±8.94 <0.001
VMOB 29.08±12.50 16.54±11.09 33.92±7.50 38.84±2.62 <0.001
VPIA 4.80±6.35 0.09±0.97 4.38±5.46 11.76±5.51 <0.001
VSOC 156.45±69.05 138.62±69.96 164.18±65.79 169.06±67.76 <0.001
Number of medications* 31.87±45.69 32.51±45.98 32.30±45.83 30.39±45.15 0.282
Main diagnosis
Fractures (n,%) 22 (1.29%) 5 (0.83%) 12 (1.81%) 5 (1.12%) <0.001#
Cancer (n,%) 317 (18.52%) 95 (15.75%) 116 (17.52%) 106 (23.71%)
Dementia (n,%) 350 (20.44%) 144 (23.88%) 141 (21.30%) 65 (14.54%)
Stroke (n,%) 138 (8.06%) 30 (4.98%) 57 (8.61%) 51 (11.41%)
Cardiovascular disease
(n,%)
209 (12.21%) 78 (12.94%) 91 (13.75%) 40 (8.95%)
Respiratory disease (n,%) 42 (2.45%) 16 (2.65%) 14 (2.11%) 12 (2.68%)
Neurologic disease (n,%) 61 (3.56%) 33 (5.47%) 16 (2.42%) 12 (2.68%)
Ipokinetic syndrome (n,%) 188 (10.98%) 37 (6.14%) 86 (12.99%) 65 (14.54%)
Other diseases (n,%) 385 (22.49%) 165 (27.36%) 129 (19.49%) 91 (20.36%)
Follow-up time (years) 3.20±2.76 4.06±2.88 2.93±2.65 2.45±2.45 <0.001
Mortality at 1 year (ev/py,
ir %)^
442/1377
(32.1%)
83/536 (15.5%) 186/523 (35.6%) 173/319 (54.3%) <0.001
Mortality at 2 years (ev/py,
ir %)^
599/2445
(24.5%)
136/986 (13.8%) 240/916 (26.2%) 223/543 (41.0%) <0.001
Mortality at 3 years (ev/py,
ir %)^
719/3317
(21.7%)
176/1368 (12.9%) 295/1228 (24.0%) 248/721 (34.4%) <0.001
VADL: activities of daily living; VCOG: cognitive status; VIP: Nursing Care Needs; VMOB: mobility; VPIA: pressure sores risk; VSOC: social support
* Number of all medications per month, taken before the patient’s enrollment
^ ev/py: events/person-years, ir%: incidence rate (number of events per 100 person-years)
doi:10.1371/journal.pone.0130946.t001
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also independent of age. The PS-quintiles adjusted HRs (95% CI) were: 0.21 (0.15–0.31), 0.26
(0.20–0.33), and 0.26 (0.20–0.35) in patients aged from 65 to 74 years, from 75 to 84 years,
and 85 years, respectively (interaction test p = 0.812). The PS-based greedy matching algo-
rithm successfully matched 547 of 1064 treated patients. Adequacy of covariate balance in the
matched sample was shown in S1 Table. Results of statin treatment effects from marginal uni-
variate Cox regression models, with robust standard errors, were fully overlapping with those
reported in Table 3 (S2 Table).
Discussion
The present retrospective observational study demonstrated that in the overall study popula-
tion of community-dwelling older patients with DM, statin treatment was associated with a
reduced three-year mortality. Importantly, the present findings demonstrated that a severely
compromised health and functional status (reflected by the MPI-SVaMA), or a very old age,
did not affect the association between statin treatment with reduced mortality. Therefore, even
Table 2. Pre-matching baseline characteristics of community-dwelling older patients with diabetes mellitus according to statin use.
Not treated (n = 648) Treated (n = 1064) p-value Standardized mean difference
Patients (%) 37.85% 62.15% —— ——
Age at SVaMA evaluation (years) 83.42±7.43 79.70±6.90 <0.001 -51.779
Sex (n males, %) 252 (38.89%) 488 (45.86%) 0.005 14.152
VCOG 5.16±3.51 4.62±3.58 0.002 -15.250
VIP 8.98±8.55 9.31±9.13 0.790 3.776
VPIA 5.23±6.53 4.53±6.22 0.022 -10.929
VADL 42.29±18.35 38.97±19.47 0.001 -17.589
VMOB 30.59±11.88 28.16±12.77 <0.001 -19.691
VSOC 163.79±67.90 151.98±69.39 0.001 -17.205
Fractures (n,%) 13 (2.01) 9 (0.85) 0.039 -9.7983
Cancer (n,%) 57 (8.80) 260 (24.44) <0.001 42.976
Dementia (n,%) 125 (19.29) 225 (21.15) 0.356 4.6236
Stroke (n,%) 52 (8.02) 86 (8.08) 0.966 0.2132
Cardiovascular disease (n,%) 73 (11.27) 136 (12.78) 0.353 4.6641
Respiratory disease (n,%) 13 (2.01) 29 (2.73) 0.351 4.7347
Neurologic disease (n,%) 14 (2.16) 47 (4.42) 0.015 12.6795
Ipokinetic syndrome (n,%) 92 (14.20) 96 (9.02) <0.001 -16.2073
Other diseases (n,%) 209 (32.25) 176 (16.54) <0.001 -37.2113
MPI-SVaMA (continuous) 0.40±0.11 0.38±0.12 <0.001 -16.481
MPI-SVaMA -1 mild risk (n,%) 188 (29.01%) 415 (39.00%) <0.001 21.209
MPI- SVaMA-2 moderate risk (n,%) 278 (42.90%) 384 (36.09%) -13.967
MPI- SVaMA-3 severe risk (n,%) 182 (28.09%) 265 (24.91%) -7.211
Number of medications* (1°tertile-Low; n,%) 298 (45.99%) 275 (25.85%) <0.001 -42.940
Number of medications* (2°tertile-Med; n,%) 204 (31.48%) 361 (33.93%) 5.218
Number of medications* (3°tertile-High; n,%) 146 (22.53%) 428 (40.23%) 38.845
VCOG: cognitive status; VIP: Nursing Care Needs; VPIA: pressure sores risk; VADL: activities of daily living; VMOB: mobility; VSOC: social support; MPI:
Multidimensional Prognostic Index
MPI-SVaMA: Multidimensional Prognostic Index based on the Standardized Multidimensional Assessment Schedule for Adults and Aged Persons
* Number of all medications prescribed within one year before patient’s enrollment
doi:10.1371/journal.pone.0130946.t002
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a severe multidimensional impairment or a very advanced age should not be considered as con-
traindications to statin treatment in older patients with DM.
Indeed, while many studies have established statin efficacy in cardiovascular prevention in
middle-aged people, only few studies have suggested a reduced mortality in older patients
treated with statins [1]. Moreover, no previous study has explored the interaction of statin
treatment with individual mortality risk in frail older patients with DM. In agreement with
recent studies [8], we found that statin treatment was underrepresented in this older popula-
tion with DM, i.e., the prevalence of statin use was only 22.7%. The patients in the present
study belonged to a population of frail older patients who underwent a CGA based on the
SVaMA in order to assess needs for support (homecare services or nursing home admission)
by the NHS. Therefore, we cannot exclude that the low prevalence of statin use may reflect the
reluctance of physicians to treat older patients with frequent clinical, functional, and social
impairments, that is frailty. Actually, notwithstanding indications, the statin-treated patients
were significantly younger, had lower functional, cognitive, and clinical impairments, and they
had a significant lower mortality risk than untreated patients. To address this selection bias, PS
methods were used to define cohorts which only differed for the treatment with statins. Both
the PS-adjusted models and the analyses within the PS-matched cohorts confirmed that the
benefit from statin treatment was evident in DM patients independently of the MPI risk grade.
The subgroup analyses for heterogeneity, moreover, showed that the effect of statin treatment
was not significantly different among patients with different mortality risks. Thus, patients
who were less frequently prescribed statins, with higher MPI-SVaMA scores, showed a larger
clinical benefit in terms of reduced mortality. Consequently, statin treatment reduced their risk
to the same level of older patients at lower mortality risk, as assessed with the MPI score.
Although we did not have laboratory assessment to support a cholesterol-related role of statins
on mortality, a growing body of evidence suggested that total cholesterol level has little rela-
tionship to mortality in older patients with statin treatment [24]. This may indicate that anti-
inflammatory, antioxidant, or other “pleiotropic” effects may play a role for reduction of mor-
tality [4]. Conversely, there was a well-established correlation linking low total cholesterol,
low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol to
increased mortality in older age [25]. Furthermore, multidimensional impairment assessed by
the MPI was also associated with low total, LDL, and HDL cholesterol [26], suggesting that
higher total cholesterol may be paradoxically associated with better survival as an example of
“reverse epidemiology” [4]. At present, the impact of statin treatment in older subjects on out-
comes such as frailty, physical and cognitive function, and institutionalization is controversial
[9–12]. In particular, in a prospective study of more than 25,000 women 65 years old or older
who were initially free of frailty, current use of statin medications was not significantly related
to the development of frailty at three-year follow-up [10]. Furthermore, in a recent population-
base study, frail men were more likely to be institutionalized and die than non-frail men, inde-
pendent of their statin exposure [12].
To evaluate the mortality risk in this older population, we adopted the MPI [19] based on
the SVaMA [20], a well calibrated and highly accurate predictor of mortality in this age group
[17, 27]. The MPI-SVaMA domain variables included multidimensional and integrated infor-
mation on clinical, functional, cognitive, and social status of patients. This approach identified
frailty as a composition of multisystemic changes occurring in older subjects that may deter-
mine an increased risk for adverse health outcomes, including death [18]. Accordingly, the
MPI score was very effective in predicting mortality in different settings. Indeed, a large multi-
centre study performed in over 2000 hospitalized older patients demonstrated that MPI had a
significantly higher predictive power for all-cause mortality compared with three other widely
diffused frailty instruments [28]. Furthermore, we obtained consistent results with various
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analytical approaches, including careful PS adjustment and matching. We must also acknowl-
edge limitations of the study. Firstly, we considered the effectiveness of statins only in terms of
reduced all-cause mortality, not taking into account causes of deaths nor nonfatal events. Nev-
ertheless, considering the net clinical benefit, a reduced total mortality is probably very relevant
in older subjects with a reduced life expectancy. Secondly, the present findings were observa-
tional and noninterventional. Given the lack of randomization to statin treatment, we cannot
exclude that a better chance of survival was considered among the motivation to start statins.
However, no RCTs of statins have so far included persons older than 82 years at baseline [1]
and we therefore need observational studies in frail older subjects to cumulate evidence for
treatment decisions. This is supported by a very recent Cochrane review assessing the impact
of study design on the effect measures estimated that demonstrated no significant differences
between observational studies and RCTs, regardless of specific observational study design, het-
erogeneity, or inclusion of studies of pharmacological interventions [29]. Furthermore, we did
not have laboratory variables (serum lipids, cholesterol, triglycerides, glucose, or glycosylated
haemoglobin) available for our analysis. the number of medications is the same among the
three groups of risk (table). In the present study, among the three MPI- SVaMA grades linked
to a different mortality risk, no differences were found for the number of medications. In the
severe risk group (MPI- SVaMA-3), one would expect a higher number of medications suggest-
ing probably an undertreatment in this group of subjects probably due to the reluctance of phy-
sicians to expose to polypharmacy the more impaired older frail patients. Finally, since the
follow-up of these patients was limited to three years, we cannot exclude that significant differ-
ences in effectiveness among patients with different mortality risk could emerge with longer
follow-up. Nevertheless, three years can be assumed to be a substantial follow-up period in this
older and frail population with high mortality risk.
The present findings suggested that statin treatment could be implemented also in older
frail patients with DM, with some consequences for the multidimensional management of
patients requiring support from the NHS. The reduced mortality associated with statin use in
these community-dwelling frail older patients with DMmay suggest a significant impact of
statin treatment also in patients requiring homecare services or nursing home admission. This
could have important policy implications for the burden that frail older patients with DMmay
pose on the NHS and healthcare systems worldwide. Only 31.8% of patients who had a cardiac
hospitalization and then were discharged to a nursing home received a statin [30]. However,
further real-world trials specifically designed for frail older patients with DM are needed to
confirm the impact of statins on survival and other clinical outcomes in this particular
subgroup.
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